ADC vs CAR-T (Heme) — Oncology Deal Terms Comparison
Market Analysis
In oncology, ADC and CAR-T (Heme) represent two of the most actively transacted modalities. At Phase 2, ADC deals carry a median total deal value of $2.6B with $411M upfront, compared to $2.0B total value and $309M upfront for CAR-T (Heme). The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do ADC and CAR-T (Heme) deal terms compare in oncology?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating